{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T03:54:50Z","timestamp":1793418890521,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T00:00:00Z","timestamp":1556755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T00:00:00Z","timestamp":1556755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic hepatitis viral infection, alcoholic intoxication, and obesity cause liver fibrosis, which progresses to decompensated liver cirrhosis, a disease for which medical demands cannot be met. Since there are currently no approved anti-fibrotic therapies for established liver fibrosis, the development of novel modalities is required to improve patient prognosis. In this study, we clarified the anti-fibrotic effects of cell sheets produced from human bone marrow-derived mesenchymal stem cells (MSCs) incubated on a temperature-sensitive culture dish with the chemical compound IC-2. Orthotopic transplantation of IC-2-engineered MSC sheets (IC-2 sheets) remarkably reduced liver fibrosis induced by chronic CCl<jats:sub>4<\/jats:sub> administration. Further, the marked production of fibrolytic enzymes such as matrix metalloproteinase (MMP)-1 and MMP-14, as well as thioredoxin, which suppresses hepatic stellate cell activation, was observed in IC-2 sheets. Moreover, the anti-fibrotic effect of IC-2 sheets was much better than that of MSC sheets. Finally, knockdown experiments revealed that MMP-14 was primarily responsible for the reduction of liver fibrosis. Here, we show that IC-2 sheets could be a promising therapeutic option for established liver fibrosis.<\/jats:p>","DOI":"10.1038\/s41598-019-43298-0","type":"journal-article","created":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T10:03:26Z","timestamp":1556791406000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Reversal of established liver fibrosis by IC-2-engineered mesenchymal stem cell sheets"],"prefix":"10.1038","volume":"9","author":[{"given":"Noriko","family":"Itaba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Kono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Yokobata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Oka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiko","family":"Osaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3633-8121","authenticated-orcid":false,"given":"Hiroki","family":"Kakuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goshi","family":"Shiota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,2]]},"reference":[{"key":"43298_CR1","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","volume":"14","author":"T Tsuchida","year":"2017","unstructured":"Tsuchida, T. & Friedman, S. L. Mechanisms of hepatic stellate cell activation. Nat. Rev. Gastroenterol. Hepatol. 14, 397\u2013411 (2017).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"43298_CR2","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1056\/NEJM199304223281620","volume":"328","author":"SL Friedman","year":"1993","unstructured":"Friedman, S. L. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N. Engl. J. Med. 328, 1828\u20131835 (1993).","journal-title":"N. Engl. J. Med."},{"key":"43298_CR3","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1056\/NEJMra1504367","volume":"375","author":"PS Ge","year":"2016","unstructured":"Ge, P. S. & Runyon, B. A. Treatment of patients with cirrhosis. N. Engl. J. Med. 375, 767\u2013777 (2016).","journal-title":"N. Engl. J. Med."},{"key":"43298_CR4","doi-asserted-by":"publisher","first-page":"S750","DOI":"10.1093\/infdis\/jix382","volume":"16","author":"TH Su","year":"2017","unstructured":"Su, T. H. & Kao, J. H. Unmet needs in clinical and basic hepatitis B virus research. J. Infect. Dis. 16, S750\u2013S756 (2017).","journal-title":"J. Infect. Dis."},{"key":"43298_CR5","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/j.jhep.2015.02.039","volume":"62","author":"C Trautwein","year":"2015","unstructured":"Trautwein, C., Friedman, S. L., Schuppan, D. & Pinzani, M. Hepatic fibrosis: concept to treatment. J. Hepatol. 62, S15\u201324 (2015).","journal-title":"J. Hepatol."},{"key":"43298_CR6","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/hep.27720","volume":"62","author":"NJ Torok","year":"2015","unstructured":"Torok, N. J., Dranoff, J. A., Schuppan, D. & Friedman, S. L. Strategies and endpoint of antifibrotic drug trials: summary and recommendations from the AASLD emerging trends conference, Chicago, June 2014. Hepatology 62, 627\u2013634 (2015).","journal-title":"Hepatology"},{"key":"43298_CR7","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1002\/hep.25670","volume":"56","author":"DY Zhang","year":"2012","unstructured":"Zhang, D. Y. & Friedman, S. L. Fibrosis-dependent mechanisms of hepatocarcinogenesis. Hepatology 56, 769\u2013775 (2012).","journal-title":"Hepatology"},{"key":"43298_CR8","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jceh.2017.08.001","volume":"7","author":"NS Choudhary","year":"2017","unstructured":"Choudhary, N. S., Saraf, N., Saigal, S. & Soin, A. S. Liver transplantation for acute on chronic liver failure. J. Clin. Exp. Hepatol. 7, 247\u2013252 (2017).","journal-title":"J. Clin. Exp. Hepatol."},{"key":"43298_CR9","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1002\/lt.22083","volume":"16","author":"BM Stutchfield","year":"2010","unstructured":"Stutchfield, B. M., Forbes, S. J. & Wigmore, S. J. Prospects for stem cell transplantation in the treatment of hepatic disease. Liver Transpl. 16, 827\u2013836 (2010).","journal-title":"Liver Transpl."},{"key":"43298_CR10","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1053\/j.gastro.2008.03.015","volume":"134","author":"TK Kuo","year":"2008","unstructured":"Kuo, T. K. et al. Stem cell therapy for liver disease: parameters governing the success of using bone marrow mesenchymal stem cells. Gastroenterology 134, 2111\u20132121 (2008).","journal-title":"Gastroenterology"},{"key":"43298_CR11","doi-asserted-by":"publisher","first-page":"860578","DOI":"10.1155\/2011\/860578","volume":"2011","author":"MA Puglisi","year":"2011","unstructured":"Puglisi, M. A. et al. Therapeutic implications of mesenchymal stem cells in liver injury. J. Biomed. Biotechnol. 2011, 860578 (2011).","journal-title":"J. Biomed. Biotechnol."},{"key":"43298_CR12","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/hepr.12747","volume":"47","author":"G Shiota","year":"2017","unstructured":"Shiota, G. & Itaba, N. Progress in stem cell-based therapy for liver disease. Hepatol. Res. 47, 127\u2013141 (2017).","journal-title":"Hepatol. Res."},{"key":"43298_CR13","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.1002\/stem.1818","volume":"32","author":"V Volarevic","year":"2014","unstructured":"Volarevic, V., Nurkovic, J., Arsenijevic, N. & Stojkovic, M. Concise review: Therapeutic potential of mesenchymal stem cells for the treatment of acute liver failure and cirrhosis. Stem Cells 32, 2818\u20132823 (2014).","journal-title":"Stem Cells"},{"key":"43298_CR14","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13287-018-0816-2","volume":"9","author":"L Zhao","year":"2018","unstructured":"Zhao, L., Chen, S., Shi, X., Cao, H. & Li, L. A pooled analysis of mesenchymal stem cell-based therapy for liver disease. Stem Cell Res. Ther. 9, 72 (2018).","journal-title":"Stem Cell Res. Ther."},{"key":"43298_CR15","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1053\/j.gastro.2017.09.049","volume":"154","author":"CW Lee","year":"2018","unstructured":"Lee, C. W., Chen, Y. F., Wu, H. H. & Lee, O. K. Historical perspectives and advances in mesenchymal stem cell research for the treatment of liver diseases. Gastroenterology 154, 46\u201356 (2018).","journal-title":"Gastroenterology"},{"key":"43298_CR16","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.jhep.2018.01.030","volume":"68","author":"M Alfaifi","year":"2018","unstructured":"Alfaifi, M., Eom, Y. W., Newsome, P. N. & Baik, S. K. Mesenchymal stromal cell therapy for liver diseases. J. Hepatol. 68, 1272\u20131285 (2018).","journal-title":"J. Hepatol."},{"key":"43298_CR17","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/nm1576","volume":"13","author":"K Ohashi","year":"2007","unstructured":"Ohashi, K. et al. Engineering functional two- and three-dimensional liver systems in vivo using hepatic tissue sheets. Nat. Med. 13, 880\u2013885 (2007).","journal-title":"Nat. Med."},{"key":"43298_CR18","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/j.jtcvs.2005.07.023","volume":"130","author":"IA Memon","year":"2005","unstructured":"Memon, I. A. et al. Repair of impaired myocardium by means of implantation of engineered autologous myoblast sheets. J. Thorac. Cardiovasc. Surg. 130, 1333\u20131341 (2005).","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"43298_CR19","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1152\/ajpgi.00187.2007","volume":"293","author":"Y Yoshida","year":"2007","unstructured":"Yoshida, Y. et al. A role of Wnt\/beta-catenin signals in hepatic fate specification of human umbilical cord blood-derived mesenchymal stem cells. Am. J. Physiol. Gastrointest. Liver Physiol. 293, 1089\u20131098 (2007).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"43298_CR20","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1111\/j.1872-034X.2007.00162.x","volume":"37","author":"T Shimomura","year":"2007","unstructured":"Shimomura, T. et al. Hepatic differentiation of human bone marrow-derived UE7T-13 cells: effects of cytokines and CCN family gene expression. Hepatol. Res. 37, 1068\u20131079 (2007).","journal-title":"Hepatol. Res."},{"key":"43298_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/srep16169","volume":"10","author":"N Itaba","year":"2015","unstructured":"Itaba, N. et al. Human mesenchymal stem cell-engineered hepatic cell sheets accelerate liver regeneration in mice. Sci. Rep. 10, 16169 (2015).","journal-title":"Sci. Rep."},{"key":"43298_CR22","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.reth.2015.10.001","volume":"2","author":"N Itaba","year":"2015","unstructured":"Itaba, N. et al. Identification of the small molecule compound which induces hepatic differentiation of human mesenchymal stem cells. Regen. Ther. 2, 32\u201341 (2015).","journal-title":"Regen. Ther."},{"key":"43298_CR23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.reth.2018.07.001","volume":"9","author":"N Itaba","year":"2018","unstructured":"Itaba, N. et al. Hepatic cell sheets engineered from human mesenchymal stem cells with a single small molecule compound IC-2 ameliorate acute liver injury in mice. Regen. Ther. 9, 45\u201357 (2018).","journal-title":"Regen. Ther."},{"key":"43298_CR24","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1172\/JCI24798","volume":"115","author":"TI Novobrantseva","year":"2005","unstructured":"Novobrantseva, T. I. et al. Attenuated liver fibrosis in the absence of B cells. J. Clin. Invest. 115, 3072\u20133082 (2005).","journal-title":"J. Clin. Invest."},{"key":"43298_CR25","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.matbio.2018.04.006","volume":"68","author":"D Schuppan","year":"2018","unstructured":"Schuppan, D., Ashfaq-Khan, M., Yang, A. T. & Kim, Y. O. Liver fibrosis: Direct antifibrotic agents and targeted therapies. Matrix Biol. 68, 435\u2013451 (2018).","journal-title":"Matrix Biol."},{"key":"43298_CR26","doi-asserted-by":"publisher","first-page":"C789","DOI":"10.1152\/ajpcell.00230.2013","volume":"305","author":"A Malla","year":"2013","unstructured":"Malla, A. & Lotersztajn, S. Cellular mechanisms of tissue fibrosis. 5. Novel insights into liver fibrosis. Am. J. Physiol. Cell Physiol. 305, C789\u2013C799 (2013).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"43298_CR27","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1053\/j.gastro.2016.12.003","volume":"152","author":"SY An","year":"2017","unstructured":"An, S. Y. et al. Milk fat globule-EGF factor 8, secreted by mesenchymal stem cells, protects against liver fibrosis in mice. Gastroenterology 152, 1174\u20131186 (2017).","journal-title":"Gastroenterology"},{"key":"43298_CR28","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/jcp.25921","volume":"233","author":"H Shimizu","year":"2018","unstructured":"Shimizu, H., Tsubota, T., Kanki, K. & Shiota, G. All-trans retinoic acid ameliorates hepatic stellate cell activation via suppression of thioredoxin interacting protein expression. J. Cell. Physiol. 233, 607\u2013616 (2018).","journal-title":"J. Cell. Physiol."},{"key":"43298_CR29","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jhep.2004.09.020","volume":"42","author":"H Okuyama","year":"2005","unstructured":"Okuyama, H. et al. Overexpression of thioredoxin prevents thioacetamide-induced hepatic fibrosis in mice. J. Hepatol. 42, 117\u2013123 (2005).","journal-title":"J. Hepatol."},{"key":"43298_CR30","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1002\/jcp.24650","volume":"229","author":"CJ Foley","year":"2014","unstructured":"Foley, C. J. & Kuliopulos, A. Mouse matrix metalloproteinase-1a (Mmp1a) gives new insight into MMP function. J. Cell. Physiol. 229, 1875\u20131880 (2014).","journal-title":"J. Cell. Physiol."},{"key":"43298_CR31","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.bbadis.2017.12.001","volume":"1864","author":"B\u00d6 Akcora","year":"2018","unstructured":"Akcora, B. \u00d6., Storm, G. & Bansal, R. Inhibition of canonical WNT signaling pathway by \u03b2-catenin\/CBP inhibitor ICG-001 ameliorates liver fibrosis in vivo through suppression of stromal CXCL12. Biochim. Biophys. Acta. Mol. Basis Dis. 1864, 804\u2013818 (2018).","journal-title":"Biochim. Biophys. Acta. Mol. Basis Dis."},{"key":"43298_CR32","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ebiom.2017.08.016","volume":"23","author":"K Kimura","year":"2017","unstructured":"Kimura, K. et al. Safety, tolerability, and preliminary efficacy of the anti-fibrotic small molecule PRI-724, a CBP\/\u03b2-catenin inhibitor, in patients with hepatitis C virus-related cirrhosis: A single-center, open-label, dose escalation phase 1 trial. EBioMedicine 23, 79\u201387 (2017).","journal-title":"EBioMedicine"},{"key":"43298_CR33","doi-asserted-by":"publisher","first-page":"e0160581","DOI":"10.1371\/journal.pone.0160581","volume":"11","author":"C Xie","year":"2016","unstructured":"Xie, C. et al. Quantification of hepatic vascular and parenchymal regeneration in mice. PLoS One 11, e0160581 (2016).","journal-title":"PLoS One"},{"key":"43298_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1055\/s-2008-1040452","volume":"10","author":"D Schuppan","year":"1990","unstructured":"Schuppan, D. Structure of the extracellular matrix in normal and fibrotic liver: collagens and glycoproteins. Semin. Liver Dis. 10, 1\u201310 (1990).","journal-title":"Semin. Liver Dis."},{"key":"43298_CR35","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/j.bbamcr.2017.04.015","volume":"1864","author":"S Amar","year":"2017","unstructured":"Amar, S., Smith, L. & Fields, G. B. Matrix metalloproteinase collagenolysis in health and disease. Biochim. Biophys. Acta. 1864, 1940\u20131951 (2017).","journal-title":"Biochim. Biophys. Acta."},{"key":"43298_CR36","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.jmb.2007.02.076","volume":"368","author":"M Gioia","year":"2007","unstructured":"Gioia, M. et al. Characterization of the mechanisms by which gelatinase A, neutrophil collagenase, and membrane-type metalloproteinase MMP-14 recognize collagen I and enzymatically process the two alpha-chains. J. Mol. Biol. 368, 1101\u20131113 (2007).","journal-title":"J. Mol. Biol."},{"key":"43298_CR37","doi-asserted-by":"publisher","first-page":"5872","DOI":"10.1074\/jbc.270.11.5872","volume":"270","author":"RT Aimes","year":"1995","unstructured":"Aimes, R. T. & Quigley, J. P. Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3\/4- and 1\/4-length fragments. J. Biol. Chem. 270, 5872\u20135876 (1995).","journal-title":"J. Biol. Chem."},{"key":"43298_CR38","doi-asserted-by":"publisher","first-page":"17119","DOI":"10.1074\/jbc.271.29.17119","volume":"19","author":"H Will","year":"1996","unstructured":"Will, H., Atkinson, S. J., Butler, G. S., Smith, B. & Murphy, G. The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation. Regulation by TIMP-2 and TIMP-3. J. Biol. Chem. 19, 17119\u201317123 (1996).","journal-title":"J. Biol. Chem."},{"key":"43298_CR39","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0014-5793(02)03654-2","volume":"532","author":"V Kn\u00e4uper","year":"2002","unstructured":"Kn\u00e4uper, V. et al. Cellular activation of proMMP-13 by MT1-MMP depends on the C-terminal domain of MMP-13. FEBS Lett. 532, 127\u2013130 (2002).","journal-title":"FEBS Lett."},{"key":"43298_CR40","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/(SICI)1098-2744(199806)22:2<84::AID-MC3>3.0.CO;2-K","volume":"22","author":"H Li","year":"1998","unstructured":"Li, H. et al. Immunological characterization of cell-surface and soluble forms of membrane type 1 matrix metalloproteinase in human breast cancer cells and in fibroblasts. Mol. Carcinog. 22, 84\u201394 (1998).","journal-title":"Mol. Carcinog."},{"key":"43298_CR41","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1042\/BJ20041324","volume":"387","author":"M Toth","year":"2005","unstructured":"Toth, M. et al. Cleavage at the stem region releases an active ectodomain of the membrane type 1 matrix metalloproteinase. Biochem. J. 387, 497\u2013506 (2005).","journal-title":"Biochem. J."},{"key":"43298_CR42","first-page":"3175","volume":"41","author":"C Du","year":"2018","unstructured":"Du, C. et al. Transplantation of human matrix metalloproteinase-1 gene-modified bone marrow-derived mesenchymal stem cell attenuates CCl4-induced liver fibrosis in rats. Int. J. Mol. Med. 41, 3175\u20133184 (2018).","journal-title":"Int. J. Mol. Med."},{"key":"43298_CR43","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/sj.thj.6200232","volume":"4","author":"A Tocci","year":"2003","unstructured":"Tocci, A. & Forte, L. Mesenchymal stem cell: use and perspectives. Hematol. J. 4, 92\u201396 (2003).","journal-title":"Hematol. J."},{"key":"43298_CR44","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.stemcr.2013.06.001","volume":"1","author":"Y Mabuchi","year":"2013","unstructured":"Mabuchi, Y. et al. LNGFR(+)THY-1(+)VCAM-1(hi+) cells reveal functionally distinct subpopulations in mesenchymal stem cells. Stem Cell Reports 1, 152\u2013165 (2013).","journal-title":"Stem Cell Reports"},{"key":"43298_CR45","first-page":"1701","volume":"18","author":"S Hazra","year":"2012","unstructured":"Hazra, S. et al. Modulation of matrix metalloproteinase activity by EDTA prevents posterior capsular opacification. Mol. Vis. 18, 1701\u20131711 (2012).","journal-title":"Mol. Vis."},{"key":"43298_CR46","first-page":"3","volume":"1","author":"P Lu","year":"2011","unstructured":"Lu, P., Takai, K., Weaver, V. M. & Werb, Z. Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harb. Perspect. Biol. 1, 3 (2011).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"43298_CR47","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1074\/jbc.272.4.2446","volume":"272","author":"E Ohuchi","year":"1997","unstructured":"Ohuchi, E. et al. Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J. Biol. Chem. 272, 2446\u20132451 (1997).","journal-title":"J. Biol. Chem."},{"key":"43298_CR48","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.jhep.2016.01.004","volume":"64","author":"Y Nagamoto","year":"2016","unstructured":"Nagamoto, Y. et al. Transplantation of a human iPSC-derived hepatocyte sheet increases survival in mice with acute liver failure. J. Hepatol. 64, 1068\u20131075 (2016).","journal-title":"J. Hepatol."},{"key":"43298_CR49","doi-asserted-by":"publisher","first-page":"549","DOI":"10.3727\/096368915X688669","volume":"25","author":"Z Baimakhanov","year":"2016","unstructured":"Baimakhanov, Z. et al. Efficacy of multilayered hepatocyte sheet transplantation for radiation-induced liver damage and partial hepatectomy in a rat model. Cell Transplant. 25, 549\u2013558 (2016).","journal-title":"Cell Transplant."},{"key":"43298_CR50","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.gie.2015.01.062","volume":"82","author":"M Maeda","year":"2015","unstructured":"Maeda, M. et al. Endoscopic cell sheet transplantation device developed by using a 3-dimensional printer and its feasibility evaluation in a porcine model. Gastrointest. Endosc. 82, 147\u2013152 (2015).","journal-title":"Gastrointest. Endosc."},{"key":"43298_CR51","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/jgm.583","volume":"6","author":"Y Takeda","year":"2004","unstructured":"Takeda, Y. et al. Can the life span of human marrow stromal cells be prolonged by bmi\u20101, E6, and E7 and\/or telomerase without affecting cardiomyogenic differentiation? J. Gene Med. 6, 833\u2013845 (2004).","journal-title":"J. Gene Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-43298-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-43298-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-43298-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T09:11:07Z","timestamp":1671268267000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-43298-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,2]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["43298"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-43298-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,2]]},"assertion":[{"value":"12 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.S. holds more than 5% of the total shares of KanonCure Inc. and receives compensation as a member of KanonCure Inc. Y.K. is employed by KanonCure Inc. The other authors have no competing interests to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"6841"}}